Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.

Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.

Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.

At the 38th Society for Immunotherapy of Cancer Meeting, Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126, revolutionizing new antibody-related therapies.

Kodiak Sciences recently revealed that its Phase III GLOW study of tarcocimab tedromer, a 5 mg ABC therapy for moderate to severe NPDR, met its primary one-year endpoint.

Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).

Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.

TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.

Clinical-stage biopharmaceutical firm Inhibrx declared initial Phase 1 trial results for INBRX-109, used with Irinotecan and Temozolomide, to treat advanced, non-removable Ewing sarcoma. The trial focused on efficacy and safety.

IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.

Fresenius Kabi made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.